Research programme: depression therapy - Abiogen
Alternative Names: ABIO 09/01; ABIO 0901Latest Information Update: 21 Aug 2019
At a glance
- Originator University of Reading
- Developer Abiogen Pharma
- Class Antidepressants; Anxiolytics; Isoxazoles
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder
- Discontinued Anxiety disorders
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in Italy
- 11 Aug 2010 BTG 1675A is still in Preclinical trials for Depression in Italy